• Donor Login
  • Contact Us
  • Breakthrough T1D
T1D Fund: A Breakthrough T1D Venture
  • About
  • Investment Strategy
  • Portfolio
  • Our Team
  • News
  • Donor Login
  • Get in Touch

The T1D Fund Team

  • The Team
  • Board of Directors
  • Investment Committee
  • Partners and Advisors
Sylvia Tobé, Ph.D. Managing Director
Lucio Iannone, Ph.D. Managing Director
Dan McNamara Head of Strategy and Industry Engagement
Eric Shen Chief of Staff
Daniel Flicker, Ph.D. Principal
Peyman Hosseinchi Senior Associate
Valerie Su, Ph.D. Associate
Morgan Janes, Ph.D. Associate
Yash Malliwal Senior Analyst
Matt Williams Director of Operations
Joe Lacher, Chair
Grant Beard
Mike Boyle
Karen Jordan
John Cammett
Aaron J. Kowalski, Ph.D.
Sylvia Tobé, Ph.D. Managing Director
Lucio Iannone, Ph.D. Managing Director
Brady Bohrmann
John Cammett
Peter Gottlieb, M.D. Professor of Pediatrics and Medicine, Barbara Davis Center, University of Colorado School of Medicine
Teresa Foy, Ph.D. Immunologist and Biopharmaceutical R&D Leader
Jason Snipe Founder & Chief Investment Officer, Odyssey Capital Advisors
Frank Martin, Ph.D. Biotechnology Venture Advisor

About the T1D Fund: A Breakthrough T1D Venture

Launched in 2016 as a wholly owned subsidiary of Breakthrough T1D, the T1D Fund is the first scaled venture fund established to catalyze the development of T1D cure-oriented therapies through investments. The Fund co-invests with venture capital firms and biopharma companies in support of early-stage companies pursuing disease-modifying therapies and potential cures for T1D. A core element of its mission is to rapidly advance promising therapies through development and ultimately regulatory approval. Led by a deeply experienced team of healthcare and investment professionals, working in partnership with an independent Investment Committee, the Fund leverages its vast research, clinical, regulatory, and medical affairs network on behalf of its portfolio companies. Funded through charitable contributions from donors and from Breakthrough T1D itself, the Fund makes investments in biotech companies and reinvests returns into new investments, thereby extending the impact of its donors’ contributions.

  • About
  • Investment
    Strategy
  • Portfolio
  • Our Team
  • News
  • Privacy Policy
Contact Us

For more information email us at info@t1dfund.org

T1D Fund: A Breakthrough T1D Venture

© Copyright 2026. All Rights Reserved